Genetics Investing News

Genetics Investing

Aviragen and Vaxart Amend Terms of Merger Agreement

Genetics Investing

Aviragen Therapeutics (NASDAQ:AVIR) and Vaxart announced that the companies have agreed to amend the terms of their previously announced merger agreement to increase the proposed ownership percentage of Aviragen stockholders of the combined company. As quoted in the press release: Wouter Latour, M.D., Chief Executive Officer of Vaxart, Inc., said, “The amended terms reflect our …

Aviragen Therapeutics (NASDAQ:AVIR) and Vaxart announced that the companies have agreed to amend the terms of their previously announced merger agreement to increase the proposed ownership percentage of Aviragen stockholders of the combined company.

As quoted in the press release:

Wouter Latour, M.D., Chief Executive Officer of Vaxart, Inc., said, “The amended terms reflect our commitment to completing the transaction with Aviragen. Our Board and management believe in the strategic value of the merger and we look forward to creating meaningful value for all stockholders.”

Click here to read the full press release.

aviragen therapeuticsmergertherapeuticsGenetics Investing

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20

COMMODITIES

Commodities
Gold1811.70+3.29
Silver19.850.00
Copper3.60-0.11
Palladium1938.50-6.50
Platinum889.00+3.00
Oil108.26+2.50
Heating Oil3.95+0.12
Natural Gas5.69+0.07

DOWNLOAD FREE REPORTS

Browse more resource reports ≫
Browse more technology reports ≫
Browse more life science reports ≫

BROWSE COMPANIES BY SECTOR

×